Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
FDA supplemental approval of labeling changes for metformin hydrochloride; this is a regulatory action, not a clinical trial, and does not report efficacy or comparative benefit data.
FDA supplemental approval of a labeling change for lamotrigine generic tablets; describes a regulatory action, not clinical evidence of efficacy or safety.